IL22 and alkaline phosphatase measurement: Therapies for AP currently under study aim to inhibit pro-inflammatory pathways, such as TNF-α, with neutralizing antibodies, or up-regulate anti-inflammatory cytokines such as IL-10 or IL-22 (Feng et al., 2012; Xue et al., 2012; Sendler et al., 2013).